Social media emerges as the primary channel for health-related scams, while influencer endorsements and AI-generated content amplify risks for consumers
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America
Approval paves the way for expansion in North America’s growing vascular access market, with innovative SlipStream technology designed to simplify catheter insertion and enhance patient care
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
Pharmaceutical R&D veteran brings over 20 years of expertise in formulation development, ANDA filings, and regulated-market product innovation to strengthen MSN Laboratories’ global growth ambitions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
